Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
3.580
-0.240 (-6.28%)
May 12, 2026, 1:36 PM EDT - Market open
Cabaletta Bio Employees
As of December 31, 2025, Cabaletta Bio had 156 total employees, including 154 full-time and 2 part-time employees. The number of employees decreased by 8 or -4.88% compared to the previous year.
Employees
156
Change
-8
Growth
-4.88%
Revenue / Employee
n/a
Profits / Employee
-$1,076,000
Market Cap
583.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 156 | -8 | -4.88% | 154 | 2 |
| Sep 30, 2025 | 151 | -4 | -2.58% | 148 | 3 |
| Jun 30, 2025 | 170 | 32 | 23.19% | 167 | 3 |
| Mar 31, 2025 | 167 | 47 | 39.17% | 163 | 4 |
| Dec 31, 2024 | 164 | 61 | 59.22% | 161 | 3 |
| Sep 30, 2024 | 155 | 61 | 64.89% | 154 | 1 |
| Jun 30, 2024 | 138 | 59 | 74.68% | 136 | 2 |
| Mar 31, 2024 | 120 | 53 | 79.10% | 118 | 2 |
| Dec 31, 2023 | 103 | 43 | 71.67% | 101 | 2 |
| Sep 30, 2023 | 94 | 35 | 59.32% | 92 | 2 |
| Jun 30, 2023 | 79 | 21 | 36.21% | 77 | 2 |
| Mar 31, 2023 | 67 | 10 | 17.54% | 66 | 1 |
| Dec 31, 2022 | 60 | 6 | 11.11% | 58 | 2 |
| Sep 30, 2022 | 59 | 12 | 25.53% | 57 | 2 |
| Jun 30, 2022 | 58 | 19 | 48.72% | 57 | 1 |
| Mar 31, 2022 | 57 | 21 | 58.33% | 56 | 1 |
| Dec 31, 2021 | 54 | 20 | 58.82% | 53 | 1 |
| Sep 30, 2021 | 47 | 15 | 46.88% | 46 | 1 |
| Jun 30, 2021 | 39 | 8 | 25.81% | 38 | 1 |
| Mar 31, 2021 | 36 | 7 | 24.14% | 35 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Arvinas | 246 |
| CorMedix | 191 |
| Sutro Biopharma | 137 |
| BridgeBio Oncology Therapeutics | 92 |
| Zevra Therapeutics | 61 |
| AgomAb Therapeutics NV | 58 |
| Altimmune | 57 |
| Candel Therapeutics | 55 |
CABA News
- 8 days ago - Cabaletta Bio financing overhang concerns should be addressed, says Cantor - TheFly
- 8 days ago - Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering - GlobeNewsWire
- 14 days ago - Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel - TheFly
- 14 days ago - Cabaletta Bio, Cellares enter 10-year commercial agreement - TheFly
- 14 days ago - Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - GlobeNewsWire
- 14 days ago - Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - Business Wire
- 14 days ago - Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting - GlobeNewsWire
- 27 days ago - Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle - TheFly